UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A quality‐adjusted survival time without symptoms or toxicities analysis of glasdegib plus low‐dose cytarabine versus low‐dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy

Cancer, 2020-10, Vol.126 (19), p.4315-4321

2020

Volltextzugriff (PDF)

Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial

Annals of hematology, 2021-05, Vol.100 (5), p.1181-1194

2021

Volltextzugriff (PDF)

Synthesis and Two-photon Photolysis of 6-(ortho-Nitroveratryl)-Caged IP3 in Living Cells

Chembiochem : a European journal of chemical biology, 2006-01, Vol.7 (1), p.174-180

2006

Volltextzugriff (PDF)

Real-World Treatment Patterns and Costs for Patients with Renal Cell Carcinoma Initiating Treatment with Sunitinib and Pazopanib

Journal of managed care & specialty pharmacy, 2016-08, Vol.22 (8), p.979-990

2016

Volltextzugriff (PDF)

Veno‐occlusive disease risk in pediatric patients with acute myeloid leukemia treated with gemtuzumab ozogamicin before allogeneic hematopoietic cell transplantation

Pediatric blood & cancer, 2021-08, Vol.68 (8), p.e29067-n/a

2021

Volltextzugriff (PDF)

A real-world, cross-sectional, community survey of symptoms and health-related quality of life of adults with acute myeloid leukemia

Future oncology (London, England), 2019-06, Vol.15 (16), p.1895-1909

2019

Volltextzugriff (PDF)

Glasdegib plus low-dose cytarabine for acute myeloid leukemia: Practical considerations from advanced practitioners and pharmacists

Journal of Oncology Pharmacy Practice, 2021-04, Vol.27 (3), p.658-672

2021

Volltextzugriff (PDF)

Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial

Annals of hematology, 2021-07, Vol.100 (7), p.1917-1918

2021

Volltextzugriff (PDF)

Expression of metabotropic glutamate receptors in nodose ganglia and the nucleus of the solitary tract

American journal of physiology. Heart and circulatory physiology, 2001-07, Vol.281 (1), p.H457-H462

2001

Volltextzugriff (PDF)

Prior Gemtuzumab Ozogamicin Exposure in Adults with Acute Myeloid Leukemia Does Not Increase Hepatic Veno-Occlusive Disease Risk after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis

Biology of blood and marrow transplantation, 2020-05, Vol.26 (5), p.884-892

2020

Volltextzugriff (PDF)

Expression of metabotropic glutamate receptor 8 in autonomic cell groups of the medulla oblongata of the rat

Brain research, 2002-12, Vol.957 (1), p.162-173

2002

Volltextzugriff (PDF)

Quality-Adjusted Survival for Low-Dose Cytarabine (LDAC) Versus Glasdegib+LDAC Among Newly Diagnosed Acute Myeloid Leukemia Patients Who Are Not Candidates for Intensive Chemotherapy: A Q-TWiST Analysis

Blood, 2019-11, Vol.134 (Supplement_1), p.2610-2610

2019

Volltextzugriff (PDF)

Cross-Sectional Survey of Symptoms and Health-Related Quality of Life of Adults with De Novo Acute Myeloid Leukemia (AML) in Clinical Practice

Blood, 2017-12, Vol.130, p.5660-5660

2017

Volltextzugriff (PDF)

Low-dose cytarabine with or without glasdegib in newly diagnosed patients with acute myeloid leukemia: Long-term analysis of a phase 2 randomized trial

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.7010-7010

2019

Volltextzugriff (PDF)

Long-term response to sunitinib treatment in metastatic renal cell carcinoma (mRCC)

Journal of clinical oncology, 2016-01, Vol.34 (2_suppl), p.598-598

2016

Volltextzugriff (PDF)

Low-Dose Cytarabine With or Without Glasdegib in Newly Diagnosed Patients with Acute Myeloid Leukemia: Long-Term Analysis of a Phase 2 Randomized Trial

Clinical lymphoma, myeloma and leukemia, 2019-09, Vol.19, p.S228-S229

2019

Volltextzugriff (PDF)

Clinical Benefit of Glasdegib Plus Low-Dose Cytarabine in Patients with De Novo and Secondary Acute Myeloid Leukemia: Long-Term Analysis of a Phase 2 Randomized Trial

Clinical lymphoma, myeloma and leukemia, 2019-09, Vol.19, p.S231-S231

2019

Volltextzugriff (PDF)

Glasdegib with LDAC in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) Unsuitable for Intensive Chemotherapy: Effects on Transfusions and Marrow Recovery vs LDAC Alone

Clinical lymphoma, myeloma and leukemia, 2019-09, Vol.19, p.S230-S230

2019

Volltextzugriff (PDF)

Prior Gemtuzumab Ozogamicin Exposure in Adults With Acute Myeloid Leukemia Does Not Increase Hepatic Veno-occlusive Disease Risk After Allogeneic Hematopoietic Cell Transplantation: a CIBMTR Analysis

Biology of blood and marrow transplantation, 2019-12, Vol.26 (5), p.884-892

2019

Volltextzugriff (PDF)

Expression of metabotropic glutamate receptors in nodose ganglia and the nucleus of the solitary tract

American journal of physiology. Heart and circulatory physiology, 2001-07, Vol.50 (1), p.H457

2001

Volltextzugriff (PDF)

Synthesis and Two‐photon Photolysis of 6‐( ortho ‐Nitroveratryl)‐Caged IP 3 in Living Cells

Chembiochem : a European journal of chemical biology, 2006-01, Vol.7 (1), p.174-180

2006

Volltextzugriff (PDF)

Veno-Occlusive Disease Characteristics in Pediatric Patients with Acute Myeloid Leukemia Receiving Gemtuzumab Ozogamicin before Allogeneic Stem Cell Transplant

Biology of blood and marrow transplantation, 2018-03, Vol.24 (3), p.S302

2018

Volltextzugriff (PDF)

435 - Veno-Occlusive Disease Characteristics in Pediatric Patients with Acute Myeloid Leukemia Receiving Gemtuzumab Ozogamicin before Allogeneic Stem Cell Transplant

Biology of blood and marrow transplantation, 2018-03, Vol.24 (3), p.S302-S302

2018

Volltextzugriff (PDF)

Characterization of Veno-Occlusive Disease (VOD) in Adult Patients (Pts) with Acute Myeloid Leukemia (AML) Receiving Gemtuzumab Ozogamicin (GO) before Allogeneic Stem Cell Transplant (SCT)

Biology of blood and marrow transplantation, 2018-03, Vol.24 (3), p.S301-S302

2018

Volltextzugriff (PDF)

434 - Characterization of Veno-Occlusive Disease (VOD) in Adult Patients (Pts) with Acute Myeloid Leukemia (AML) Receiving Gemtuzumab Ozogamicin (GO) before Allogeneic Stem Cell Transplant (SCT)

Biology of blood and marrow transplantation, 2018-03, Vol.24 (3), p.S301-S302

2018

Volltextzugriff (PDF)

1 – 25 von 91

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(81)
Mit Volltextzugriff
(83)

Publikationsform

Sprache

Englisch
(79)
Französisch
(13)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A quality‐adjusted survival time without symptoms or toxicities analysis of glasdegib plus low‐dose cytarabine versus low‐dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy

Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial

Synthesis and Two-photon Photolysis of 6-(ortho-Nitroveratryl)-Caged IP3 in Living Cells

Real-World Treatment Patterns and Costs for Patients with Renal Cell Carcinoma Initiating Treatment with Sunitinib and Pazopanib

Veno‐occlusive disease risk in pediatric patients with acute myeloid leukemia treated with gemtuzumab ozogamicin before allogeneic hematopoietic cell transplantation

A real-world, cross-sectional, community survey of symptoms and health-related quality of life of adults with acute myeloid leukemia

Glasdegib plus low-dose cytarabine for acute myeloid leukemia: Practical considerations from advanced practitioners and pharmacists

Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial

Expression of metabotropic glutamate receptors in nodose ganglia and the nucleus of the solitary tract

Prior Gemtuzumab Ozogamicin Exposure in Adults with Acute Myeloid Leukemia Does Not Increase Hepatic Veno-Occlusive Disease Risk after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis

Expression of metabotropic glutamate receptor 8 in autonomic cell groups of the medulla oblongata of the rat

Quality-Adjusted Survival for Low-Dose Cytarabine (LDAC) Versus Glasdegib+LDAC Among Newly Diagnosed Acute Myeloid Leukemia Patients Who Are Not Candidates for Intensive Chemotherapy: A Q-TWiST Analysis

Cross-Sectional Survey of Symptoms and Health-Related Quality of Life of Adults with De Novo Acute Myeloid Leukemia (AML) in Clinical Practice

Low-dose cytarabine with or without glasdegib in newly diagnosed patients with acute myeloid leukemia: Long-term analysis of a phase 2 randomized trial

Long-term response to sunitinib treatment in metastatic renal cell carcinoma (mRCC)

Low-Dose Cytarabine With or Without Glasdegib in Newly Diagnosed Patients with Acute Myeloid Leukemia: Long-Term Analysis of a Phase 2 Randomized Trial

Clinical Benefit of Glasdegib Plus Low-Dose Cytarabine in Patients with De Novo and Secondary Acute Myeloid Leukemia: Long-Term Analysis of a Phase 2 Randomized Trial

Glasdegib with LDAC in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) Unsuitable for Intensive Chemotherapy: Effects on Transfusions and Marrow Recovery vs LDAC Alone

Prior Gemtuzumab Ozogamicin Exposure in Adults With Acute Myeloid Leukemia Does Not Increase Hepatic Veno-occlusive Disease Risk After Allogeneic Hematopoietic Cell Transplantation: a CIBMTR Analysis

Expression of metabotropic glutamate receptors in nodose ganglia and the nucleus of the solitary tract

Synthesis and Two‐photon Photolysis of 6‐( ortho ‐Nitroveratryl)‐Caged IP 3 in Living Cells

Veno-Occlusive Disease Characteristics in Pediatric Patients with Acute Myeloid Leukemia Receiving Gemtuzumab Ozogamicin before Allogeneic Stem Cell Transplant

435 - Veno-Occlusive Disease Characteristics in Pediatric Patients with Acute Myeloid Leukemia Receiving Gemtuzumab Ozogamicin before Allogeneic Stem Cell Transplant

Characterization of Veno-Occlusive Disease (VOD) in Adult Patients (Pts) with Acute Myeloid Leukemia (AML) Receiving Gemtuzumab Ozogamicin (GO) before Allogeneic Stem Cell Transplant (SCT)

434 - Characterization of Veno-Occlusive Disease (VOD) in Adult Patients (Pts) with Acute Myeloid Leukemia (AML) Receiving Gemtuzumab Ozogamicin (GO) before Allogeneic Stem Cell Transplant (SCT)

Suchergebnisse filtern